BiomX Inc
Performance History
| Key Stats | |
|---|---|
| Open | $0.39 |
| Prev. Close | $0.56 |
| EPS | -0.63 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 9, 2023 |
| Dividend Yield % | - |
| Market Cap | $13.79M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 0.26 | 0.44 |
| 52 Week Range | 0.13 | 0.69 |
| Ratios | |
|---|---|
| P/B Ratio | 3.16 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | -$26.56M |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -153.05% |
| EPS | -0.63 |
Score Breakdown
All Score (41 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| PHGE | Market | |
|---|---|---|
| Value | 49 | 42 |
| Quality | 39 | 46 |
| Ownership | 16 | 39 |
| Growth | 32 | 44 |
| Dividends | - | 32 |
All Score (41 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About BiomX Inc (PHGE)
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Jonathan Eitan Solomon MBA
- Headquarters
- Ness Ziona
- Employees
- 54
Keep an eye on BiomX Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.